The use of MTX in the 6 months prior to and the 6 months following new initiation of TNFi use.
| MTX Use Following New TNFi Use | |||
|---|---|---|---|
| MTX use prior to new TNFi | Yes | No | Total |
| Yes | 108 (31%) | 41 (12%) | 149 (43%) |
| No | 21 (6%) | 174 (51%) | 195 (57%) |
| Total | 129 (37%) | 215 (63%) | |
MTX: methotrexate; TNFi: tumor necrosis factor inhibitors.